## S2 Table. Included trials' methodological limitations

Study	Methodological limitations
Shouman et al	There is no information on the randomization process and no concealment of allocation
	strategy is described, also there is not enough information to assess significant baseline
	differences between arms. Non-blinded study which may have resulted in deviation from
	intended interventions and bias in outcome measurement.
Chowdhury et al	Study was registered as a non-randomized single center study. Results to be submitted
	ClinicalTrials.gov by the sponsor or investigator but not yet posted, pending quality
	control review for apparent errors, deficiencies, or inconsistencies. Quasi-randomisation
	based on odd-even allocation suggests no allocation concealment. Non-blinded study
	which may have resulted in deviations from intended interventions and bias in outcome
	measurements.
Podder et al	Quasi-randomisation based on odd-even allocation with no allocation concealment. Non-
	blinded study which may have resulted in deviations from intended interventions and bias
	in outcome measurement.
Hashim et al	Quasi-randomisation based on odd-even allocation with no allocation concealment.
	Patients and investigators not blinded which may have resulted in deviations from
	intended interventions. Outcome assessors also probably not blinded.
Elgazzar et al	There is no information on randomization process and no concealment of allocation
	strategy is described. Not enough information to assess significant baseline differences
	between arms. The study is presented as "doble-blind" but there is no specification on how
	this was achieved (e.g., use of placebo), which may have resulted in deviations from
	intended interventions and bias in the measurement of the outcomes. It is unclear if an
	appropriate analytical approximation was used as those with clinical failure were shifted to
	an alternative management protocol with no further specifications.
Krolewiecki et al	Non-blinded study which may have resulted in deviation from intended interventions and
	bias in the measurement of some of the outcomes.
Niaee et al	Randomization sequence is described as adequately concealed but baseline differences
	between intervention groups suggest a problem with the randomization process. Important
	discrepancies in PCR positivity rates at baseline (47% in placebo, 60% in SOC, and 97%
	in Arm/Gp 3.) In addition, there is no explanation on why two control arms were
	implemented (one with placebo and the other without placebo). The study described that
	clinicians and patients were blinded but is not clear how this was achieved considering that
	in one of the control arms no placebo was used.
Ahmed et al	No concealment of the allocation strategy is mentioned, also there is not enough
	information to assess significant baseline differences between arms. Unclear whether the

	results were selected from multiple outcome measurements or analyses of the data and/or
	if the trial was analyzed as pre-specified.
Chaccour et al	No significant limitations identified.
Chachar et al	No concealment of the allocation strategy is mentioned. Non-blinded study which may
	result in deviation from intended interventions and bias in the measurement of the
	outcomes.
Babalola et al	The study was reported as "double blind" but lopinavir/ritonavir was not allowed for
	patients assigned to ivermectin arms. This strategy may have compromised the blinding of
	physicians and study personnel resulting in deviation from intended interventions and bias
	in the measurement of the outcomes.
Kirti R et al	No significant limitations.
Chahla et al	There is no information on randomization process and no concealment of allocation
Chama et ai	strategy is described, also there is not enough information to assess significant baseline
	differences between arms. Non-blinded study which may result in deviation from intended
	interventions and bias in the measurement of the outcomes.
Mohan et al	No significant limitations.
Shahbaznejad et al	No significant limitations.
Samaha et al	No concealment of the allocation strategy is mentioned. Non-blinded study which may
Samana et ai	have resulted in deviation from intended interventions and bias in the measurement of the
	outcomes.
Bukhari et al	There is no information on randomization process and no concealment of allocation
Bukilali et al	-
	strategy is described, also there is not enough information to assess significant baseline differences between arms. Non-blinded study which may have resulted in deviation from
	intended interventions and bias in the measurement of the outcomes.
01 1	
Okumus et al	No concealment of the allocation strategy is mentioned and baseline differences between
	intervention groups suggest a problem with the randomization process.
	The study was described in the protocol as "non-blinded" study which may have resulted
	in deviations from intended interventions and bias in the measurement of the outcomes.
Beltran et al	Randomization process not described, and no concealment of the allocation strategy is
	mentioned, however baseline characteristics were apparently balanced. In addition,
	appropriate blinding strategy is described.
Lopez-Medina et al	38 patients in intervention arm and 40 patients in control arm were excluded after
	randomization because of a labeling error. We assume that the chance of being excluded
	was not related to patient's prognosis hence prognostic balance was probably not affected.
Bermejo Galan et al	No significant limitations.
Pott-Junior et al	Non-blinded study which may have resulted in deviation from intended interventions and
	bias in the measurement of the outcomes.

Non-blinded study which may have resulted in deviation from intended interventions and
bias in the measurement of the outcomes.
It is not clear if those in charge of assigning recruited patients to each floor/intervention
were aware of the allocation sequence. Non-blinded study which may have resulted in
deviation from intended interventions and bias in the measurement of outcomes.
Overall, 9.3% on randomized patients excluded from analysis. 15 participants lost to
follow-up in the intervention and 17 participants in the control arm; 3 participants that died
in the control group and 2 in the intervention group due to adverse events, were also
excluded for viral clearance outcome. There is no evidence that the result was not biased
by missing outcome data.
Non-blinded study which may have resulted in deviation from intended interventions and
bias in the measurement of the outcomes.
The allocation sequence was described as adequately concealed but not enough
information available on baseline differences between intervention groups. 7 (10.4%) of
patients excluded in the intervention arm vs. 14 (18.4%) in control arm because RT-PCR
with Ct value >35 which suggests potential baseline imbalances between arms. In addition,
3 patients were lost to follow up in each arm.
There is no information on randomization process and no concealment of allocation
strategy is described, also there is not enough information to assess significant baseline
differences between arms. Non-blinded study which may have resulted in deviation from
intended interventions and bias in the measurement of the outcomes.
Although allocation concealment strategy was not appropriately described in the
manuscript, authors provided further details by email. Appropriate blinding strategy was
described.